MLTX Stock Forecast: MoonLake Immunotherapeutics Price Predictions for 2026-2027

Last close, 20 Nov 2026
$11
+0.36% on the day

The 16 Wall Street analysts covering MoonLake Immunotherapeutics hold a median 12-month price target of $30 — +171.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 14 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$942.1M
Ticker Nerd rank
14/ 100
Median analyst target
$30
Analysts covering
16
Revenue$0.0
Operating income−$61.7M
Net income−$61.8M
Free cash flow−$55.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.4%
1M
+7.3%
YTD
−16.0%
1Y
−14.8%
From 52W high
−50.0%
From 52W low
+15.9%
$10
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores MoonLake Immunotherapeutics on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
14/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
58
Growth
48
Momentum
41
Value
40
Accruals
28
Revisions
26
Quality
21
Issuance
13

Volatility (58): The share price has been relatively steady.

Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MLTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MLTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26MLTXHigh $57Median $30Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
12
Buy
2
Hold
2
Sell
$6
Low
$30
Median
$57
High

The green dot is the last close — the median target sits +171.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Oct 2026HC Wainwright & Co.ReiteratesBuy$50
13 Aug 2026HC Wainwright & Co.MaintainsBuy$45 → $50
20 July 2026HC Wainwright & Co.ReiteratesBuy$45
1 July 2026Leerink PartnersMaintainsOutperform$24 → $29
9 June 2026BTIGReiteratesBuy—
8 June 2026HC Wainwright & Co.ReiteratesBuy—
12 May 2026NeedhamMaintainsBuy—
11 May 2026HC Wainwright & Co.MaintainsBuy—
30 Mar 2026BTIGReiteratesBuy—
23 Mar 2026Wolfe ResearchUpgradeOutperform—
19 Mar 2026Rothschild & CoUpgradeBuy—
11 Mar 2026Clear StreetMaintainsBuy—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
2 Mar 2026RBC CapitalMaintainsSector Perform—
26 Feb 2026NeedhamReiteratesBuy—
24 Feb 2026OppenheimerMaintainsOutperform—
23 Feb 2026BTIGMaintainsBuy—
23 Feb 2026NeedhamMaintainsBuy—
20 Feb 2026RBC CapitalMaintainsSector Perform—
9 Feb 2026BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MLTX.

Market Radar

This page is one stock. Monday covers all of them.

MLTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MLTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, MoonLake Immunotherapeutics returned −14.8% against +6.9% for the S&P 500, dividends included.

MLTX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Jan 26Apr 26Jul 26Oct 26MLTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MLTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
4
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.5×

Cheaper than 36% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−81.5%

Higher than 16% of US stocks

Return on assets
−36.2%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MoonLake Immunotherapeutics has a market value of $942.1M and an enterprise value of $545.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$265.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$225.2M.

  • Shares outstanding: 83.6M.

  • MoonLake Immunotherapeutics employs 130 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

MLTX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MLTXMoonLake Immunotherapeutics$942.1M14
SVRASavara, Inc.$939.9M28
SPTXSeaport Therapeutics, Inc.$957.2M13
OMEROmeros Corp.$983.7M81
ANROAlto Neuroscience, Inc.$986.1M57
AKTSAktis Oncology, Inc.$892.7M2
CTYCity Therapeutics, Inc.$999.3M1

Take a look at MLTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own MoonLake Immunotherapeutics — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about MLTX

What is the MLTX stock price forecast for 2026-2027?

The 16 Wall Street analysts covering MoonLake Immunotherapeutics have a median 12-month price target of $30, with estimates ranging from $6 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MLTX stock a buy right now?

Of the 16 analysts covering MoonLake Immunotherapeutics, 12 rate it a Buy, 2 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks MoonLake Immunotherapeutics 14 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MLTX?

As at 21 Nov 2026, MoonLake Immunotherapeutics ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (58 of 100).

Will MLTX stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +171.0% from the last close, and Ticker Nerd's factor model ranks MoonLake Immunotherapeutics 14 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MLTX stock forecast for 2030?

No analyst covering MoonLake Immunotherapeutics publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MLTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $57 over the next 12 months.

How has MLTX stock performed over the past year?

MoonLake Immunotherapeutics returned -14.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MoonLake Immunotherapeutics do?

MoonLake Immunotherapeutics Class A Ordinary Shares represent ownership in MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on therapies for inflammatory skin and joint diseases. The company’s lead program is Sonelokimab, a tri-specific Nanobody designed to inhibit IL-17A and IL-17F, and it is being developed across dermatology and rheumatology indications such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.

Company

About MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics Class A Ordinary Shares represent ownership in MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on therapies for inflammatory skin and joint diseases. The company’s lead program is Sonelokimab, a tri-specific Nanobody designed to inhibit IL-17A and IL-17F, and it is being developed across dermatology and rheumatology indications such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. MoonLake’s work centers on advancing targeted immunology treatments for conditions with significant unmet medical needs, positioning the company within the broader biopharmaceutical sector. Its Class A Ordinary Shares provide public-market exposure to a company whose current business is concentrated on clinical development and related biotechnology operations.

CEO Dr. Jorge Santos da Silva Ph.D. · 130 employees · Switzerland · https://www.moonlaketx.com